NHS to rollout twice weekly testing of NHS staff

The NHS is to rollout twice weekly testing of NHS staff earlier than anticipated. The first 34 trusts should receive a kit for asymptomatic testing by the end of this week. This will benefit 250,000 staff. The tests will be rolled out to the rest of the English hospitals by the end of next week. […]

read more

NHS England to introduce ‘One Stop Shops’ for life-saving checks

In a major report, the NHS proposing to radically overhaul diagnostic services for patients, including MRI, CT and blood tests. The NHS is to set up diagnostic hubs, or ‘one stop shops’ across the country and away from hospitals. This will enable patients to be diagnosed closer to home. These community centres could be set […]

read more

NHS England need for new diagnostic services

A report from NHS England has found that the COVID-19 pandemic has identified a need for a ‘radical change’ in diagnostic services across the country. This report was close to publication before the pandemic identified additional actions needed to deliver higher quality diagnostic services. As part of this ‘radical change’ NHS England identified a number […]

read more

Molecular genetics of renal cell carcinoma

Most renal cell carcinomas (RCC) are diagnosed from studying the cells from a biopsy under a microscope (histology findings), with and without the use of antibodies to check for certain proteins in the tumour tissue (immunohistochemical examination). RCC tumours are very heterogeneous – there are many subtypes of RCC which have different appearances under the […]

read more

New test for the early detection of kidney cancer

Renal cell carcinoma (RCC) has poor survival because it does not show any symptoms at an early stage when it can be treated successfully. Researchers have developed a paper-based ‘plasmonic biosensor’ test using the detection of perilipin-2 (PLIN-2), a protein involved in the mobilisation of fat in the body, in urine to facilitate the early […]

read more

Potential kidney cancer test in development

A Swedish biotechnology company, Elypta, has recently been awarded an EU grant for the development of a new test for the diagnosis of renal cell carcinoma (RCC). The grant of £2.4m will be used to run a clinical trial to validate Elypta’s technology as a tool for monitoring patients who have been treated for RCC […]

read more
Showing all 6 results